Cannvas MedTech (CSE:MTEC) (Frankfurt:3CM) (OTC:CANVF), a leading digital cannabis education and analytics company, is pleased to announce unprecedented growth of its Cannvas.Me (www.cannvas.me) digital cannabis education platform as more global users from over 80 countries and 1,100 cities turn to Cannvas.Me for credible and evidence-based cannabis education. With user growth exceeding expectations and the platform’s global reach expanding at a rapid pace, Cannvas.Me is poised to become the household name for cannabis education all while increasing its unique dataset to paint a clearer picture of cannabis consumption across Canada.

“We are thrilled with our consistent new user acquisition and the way in which we keep existing users interested and engaged with Cannvas.Me, adding targeted new sections based on user needs including Cannvas For Her, Physician’s Corner, our upcoming Athlete’s Corner and much much more,” said Shawn Moniz, Chief Executive Officer. “With so many visitors to Cannvas.Me in such a short period of time, it’s clear not only Canadians, but the global audience of the 80 countries using our platform are starved for more in-depth evidence-based education on cannabis and understand that Cannvas has evolved into a trusted resource for physician-backed information on all aspects of the plant.”


Since the launch of Cannvas.Me in October, the educational platform has experienced a consistent month-to-month user growth of 30%, with a meteoric rise of 524% in March. The site is now on track to have over 4 million unique users accessing its free and unbiased cannabis education in 2019, with over 50 million views of Cannvas articles and courses before year’s end.

This puts Cannvas on track to have over 90% of countries around the world engaging with its content before the end of 2019.

The average session duration for Cannvas.Me users has also increased month-to-month since the site’s launch, up 10% each month in the past six months. With users spending an average of nearly 10 minutes on the site per visit.”Through a network of strategic partnerships focused on content and data sharing, coupled with a groundswell of global users looking to learn more about cannabis, Cannvas continues to outpace expectations as it surpasses growth projections,” said Steve Loutskou, Chief Operating Officer, Global Markets. “We are thrilled with these results and expect our media and advertising partners to feel the same as their products and services are reaching more relevant audiences as our revenue streams continue to grow alongside our user base.”

The Company announced that it has issued a total of 38,000 common shares at a deemed price of $0.265 per common share to a service provider pursuant to a consulting agreement entered into with the service provider.

About Cannvas MedTech Inc.
Cannvas MedTech is a leading digital cannabis education and analytics company delivering accessible and evidence-based education while harnessing the power of data to paint a clearer picture of cannabis consumption across Canada.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

For further information: ir@cannvasmedtech.com or visit cannvasmedtech.com

Related Links

https://cannvasmedtech.com

Click here to connect with Cannvas MedTech (CSE:MTEC) (Frankfurt:3CM) (OTC:CANVF) for an Investor Presentation. 

Source: www.newswire.ca

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less